Letters to the Editor

Pulmonary infiltrates following bone marrow transplantation

We read with interest the paper by Dr J H Campbell and colleagues (December 1993;48:1248-51) investigating the value of bronchoscopy and bronchoalveolar lavage in patients receiving immunosuppressive therapy during bone marrow transplantation.

We have recently conducted a similar retrospective study of patients referred to us for bronchoscopy from our renal unit over a 30 month period. Out of a total of 40 referrals 16 patients were identified as receiving immunosuppressive therapy either for their renal disease or for a transplant. A diagnosis was made in eight of these: cytomegalovirus pneumonitis (3), pneumocystis pneumonia (2), candida pneumonitis (1), invasive aspergillosis (1), and bacterial pneumonia (2). An adenocarcinoma was found at lobectomy in one patient. No opportunistic infections were subsequently identified in the remaining seven patients (median follow up 7.5 months).

If the diagnosed condition is essentially untreatable – for example, disseminated aspergillosis – then bronchoscopy and bronchoalveolar lavage will not alter the outcome. Nevertheless, in our series not all the diagnoses proved to be untreatable. This may be partly because in renal transplantation immunosuppression may be withdrawn, saving the patient by sacrificing the transplant.

In our patients, unlike those of Campbell et al, a negative result reliably excluded opportunistic infection allowing potentially toxic treatments to be discontinued. Our data confirm the usefulness of bronchoscopy and bronchoalveolar lavage in patients with renal failure receiving immunosuppressive therapy.

Michael Polkey
Jignesh Patel
P John Rees
Department of Thoracic Medicine,
Guy's Hospital,
London SE1 9RT,
UK

Surgical resection for small cell lung cancer

Dr EF Smit and others (January 1994;49:20-2) report a retrospective review of survival in 21 patients with small cell lung cancer (1 stage I, three stage II, seven stage IIA) who underwent surgical resection. Median survival was 29 months, 40 months for patients with stage I or II disease, and 20 months for those with stage IIA. They conclude from their results and those of others that curative resection offers the best chance for long term survival in patients with small cell carcinoma of the lung with very limited stage disease. Such a firm conclusion is warranted neither by their own findings nor by those of others of retrospective series and prospective studies, for the following reasons:

Survival data based on such a small number of patients have such wide confidence intervals that no firm conclusions can be drawn from them. Using information extracted from their figures we estimate a 95% CI of 16-43 months for overall median survival. Their results, together with the others they mention, do indeed suggest that surgical resection is associated with long term survival rates of around 20% in the small and highly selected group of carefully staged patients deemed to have potentially resectable stage I or II disease. Nevertheless, in only one of the studies they quote was an unconfounded comparison made between resection and no resection in a randomised trial. This was the trial conducted by Lad and colleagues1 who randomised 144 patients, all of whom had received and responded to chemotherapy, to subsequent resection or no resection. They found no significant difference in survival between the two groups.

Another important reason for being cautious about the possible role of surgical resection in the treatment of small cell lung cancer is that other groups are reporting increasingly promising long term survival rates in patients with limited disease and good performance status treated with intensive chemotherapy and thoracic radiotherapy without surgery.2 Such improvements have recently been reviewed by Aisner and Belani3 (see, in particular, pp 386-8 of their review). At present it is wise to conclude that there is still uncertainty about whether surgical resection can improve upon the results of other treatment modalities. Resolution of this uncertainty, and measurement of the size of any possible benefit from resection, requires the trial by Lad and colleagues to be supplemented by large randomised trials, making unconfounded comparisons between resection and no resection: trials in which control registries include the currently best available combinations of intensive chemotherapy and thoracic radiotherapy.

David J GIRLING
David Machin
Richard J Stephens
MRC Cancer Trials Office,
5 Shaftesbury Road,
Cambridge CB2 2BW,
UK


Authors' reply. We are grateful to Dr Girling and colleagues for their comments on our report. We agree with their conclusion that at present it is wise to conclude that there is uncertainty about the exact role of surgery in the management of small cell carcinoma of the lung. No doubt surgeons will continue to operate on palliative nodules, only to find on pathological examination that a small cell carcinoma was resected. In our study seven such patients were included.

Whether patients with a known preoperative diagnosis of stage I or II small cell carcinoma should be operated upon is therefore the issue of concern. As pointed out by Girling et al, with intensive chemoradiotherapy programmes increasingly promising long term survival rates are reported which are in the same range as the median and long term survival reported in our study. The intention of such programmes is to deliver maximum cytotoxicity to the primary site, therefore enhancing local control without compromising the chemotherapy dose intensity needed for systemic control. For two reasons surgery (with adjuvant chemotherapy) may be preferred to chemoradiotherapy. Firstly, the reported local failure rate observed in such programmes may be as high as 28%4 while with surgery this figure may be as low as 8%5. Also, only patients with good performance status are able to tolerate intensive chemoradiotherapy and surgery is a good alternative for the average elderly patient with small cell lung cancer.

Again we agree with Girling and colleagues that a randomised trial comparing initial resection (as opposed to adjacent site surgery as in the trial by Lad et al) followed by chemotherapy with the currently best available combinations of intensive chemotherapy and thoracic radiotherapy would be the best way to resolve this issue. Such a trial should include data collection on quality of life which may be quite different between these two treatment policies. A direct comparison between conventional treatment and surgery is, however, a prospective disease small cell lung cancer includes patients with stages IIIa and IIb where primary surgery would not be considered. Until such a study is performed we recommend resection of apparently operable patients with small cell lung cancer followed by chemotherapy.

P E POSTMUS
F SMIT
Department of Internal Medicine,
Maastricht University Hospital,
PO Box 30033,
9700 GB Groningen,
The Netherlands
